Kronos Bio Inc. (KRON) NASDAQ
$3.36 -0.05 (-1.47%)
Market Cap: $193.46M
As of 05/25/22 04:00 PM EDT. Market closed.
Kronos Bio Inc. (KRON) NASDAQ
$3.36 -0.05 (-1.47%)
Market Cap: $193.46M
As of 05/25/22 04:00 PM EDT. Market closed.
Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer. The company focuses on targeting dysregulated transcription factors and the regulatory networks within cells that drive cancerous growth. Kronos Bio’s lead investigational therapy is entospletinib, a selective inhibitor ... read more
Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer. The company focuses on targeting dysregulated transcription factors and the regulatory networks within cells that drive cancerous growth. Kronos Bio’s lead investigational therapy is entospletinib, a selective inhibitor targeting spleen tyrosine kinase (SYK) in development for the frontline treatment of NPM1-mutated acute myeloid leukemia (AML). The company is also developing KB-0742, an oral inhibitor of cyclin dependent kinase 9 (CDK9), for the treatment of MYC-amplified solid tumors. read less
COMPANY PROFILE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
Full Time Employees
63
URL
Address
.
PRICE CHART
From:
To:
KEY STATS
Open
$3.37
Previous Close
$3.41
Days Range
$3.21 - $3.55
52 week range
$3.37 - $28.42
Volume
506,636
Avg. Volume (30 days)
647,045
Market Cap
$193.46M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
56,732,201
Open
$3.37
Previous Close
$3.41
Days Range
$3.21 - $3.55
52 week range
$3.37 - $28.42
Volume
506,636
Avg. Volume (30 days)
647,045
Market Cap
$193.46M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
56,732,201
Open in:
Open in:
INSIDER TRANSACTIONS FOR KRONOS BIO INC
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| BISCHOFBERGER NORBERT W | President & CEO | May 18, 2022 | Buy | $3.72 | 206,198 | 768,046 | 509,609 | May 19, 2022, 06:03 PM |
| BISCHOFBERGER NORBERT W | President & CEO | May 17, 2022 | Buy | $3.83 | 90,931 | 348,529 | 303,411 | May 19, 2022, 06:03 PM |
| BISCHOFBERGER NORBERT W | President & CEO | May 19, 2022 | Buy | $3.78 | 300,000 | 1,134,510 | 809,609 | May 19, 2022, 06:03 PM |
| Dinsmore Christopher | Chief Scientific Officer | Dec 13, 2021 | Sale | $12.37 | 11,386 | 140,845 | 85,148 | Dec 15, 2021, 05:08 PM |
| DiMartino Jorge | Chief Medical Officer & VP | Dec 13, 2021 | Sale | $12.37 | 16,402 | 202,893 | 117,785 | Dec 15, 2021, 05:06 PM |
| BISCHOFBERGER NORBERT W | President & CEO | Dec 06, 2021 | Buy | $12.09 | 14,356 | 173,492 | 212,480 | Dec 08, 2021, 06:21 PM |
| De Backer Marianne | Director | Dec 01, 2021 | Buy | $11.57 | 1,150 | 13,305 | 2,750 | Dec 02, 2021, 05:12 PM |
| Dinsmore Christopher | Chief Scientific Officer | Oct 04, 2021 | Option Exercise | $3.27 | 9,189 | 30,048 | 105,549 | Oct 04, 2021, 06:24 PM |
| Dinsmore Christopher | Chief Scientific Officer | Oct 04, 2021 | Sale | $20.81 | 9,189 | 191,195 | 96,360 | Oct 04, 2021, 06:24 PM |
| Dinsmore Christopher | Chief Scientific Officer | Sep 07, 2021 | Option Exercise | $3.27 | 9,189 | 30,048 | 105,549 | Sep 09, 2021, 01:23 PM |
| Dinsmore Christopher | Chief Scientific Officer | Sep 07, 2021 | Sale | $21.91 | 9,189 | 201,302 | 96,360 | Sep 09, 2021, 01:23 PM |
| De Backer Marianne | Director | Aug 20, 2021 | Buy | $19.56 | 1,000 | 19,565 | 1,600 | Aug 24, 2021, 07:24 PM |
| Dinsmore Christopher | Chief Scientific Officer | Aug 02, 2021 | Option Exercise | $3.27 | 9,189 | 30,048 | 105,549 | Aug 03, 2021, 05:13 PM |
| Dinsmore Christopher | Chief Scientific Officer | Aug 02, 2021 | Sale | $20.59 | 9,189 | 189,165 | 96,360 | Aug 03, 2021, 05:13 PM |
| Loven Jakob | Director | Apr 20, 2021 | Sale | $20.10 | 21,551 | 433,185 | 1,301,556 | Apr 20, 2021, 06:59 PM |
| Loven Jakob | Director | Apr 19, 2021 | Sale | $20.59 | 14,004 | 288,278 | 1,327,245 | Apr 20, 2021, 06:59 PM |
| Loven Jakob | Director | Apr 16, 2021 | Sale | $21.01 | 33,162 | 696,762 | 1,344,962 | Apr 20, 2021, 06:59 PM |
| Loven Jakob | Director | Apr 15, 2021 | Sale | $21.78 | 24,818 | 540,536 | 1,370,254 | Apr 15, 2021, 06:57 PM |
| Loven Jakob | Director | Apr 14, 2021 | Sale | $22.80 | 32,636 | 744,029 | 1,414,010 | Apr 15, 2021, 06:57 PM |
| Loven Jakob | Director | Apr 13, 2021 | Sale | $23.84 | 17,020 | 405,793 | 1,434,731 | Apr 15, 2021, 06:57 PM |
| Loven Jakob | Director | Apr 08, 2021 | Sale | $27.41 | 63,128 | 1,730,487 | 1,507,032 | Apr 12, 2021, 08:33 PM |
| Loven Jakob | Director | Apr 12, 2021 | Sale | $26.28 | 15,828 | 415,896 | 1,444,828 | Apr 12, 2021, 08:33 PM |
| Loven Jakob | Director | Apr 09, 2021 | Sale | $27.20 | 21,660 | 589,152 | 1,460,556 | Apr 12, 2021, 08:33 PM |
| Omega Fund V, L.P. | 10% Owner | Oct 14, 2020 | Option Exercise | $16.15 | 366,299 | 5,915,729 | 3,368,283 | Oct 16, 2020, 03:58 PM |
| Omega Fund V, L.P. | 10% Owner | Oct 14, 2020 | Buy | $19.00 | 450,000 | 8,550,000 | 3,818,283 | Oct 16, 2020, 03:58 PM |
| Stampacchia Otello | Director | Oct 14, 2020 | Option Exercise | $16.15 | 366,299 | 5,915,729 | 3,368,283 | Oct 16, 2020, 03:56 PM |
| Stampacchia Otello | Director | Oct 14, 2020 | Buy | $19.00 | 450,000 | 8,550,000 | 3,818,283 | Oct 16, 2020, 03:56 PM |
| TANEN DAVID M | Director | Oct 14, 2020 | Option Exercise | $16.15 | 37,119 | 599,472 | 471,230 | Oct 16, 2020, 03:54 PM |
| Ridloff Elena | Director | Oct 14, 2020 | Buy | $19.00 | 2,630 | 49,970 | 2,630 | Oct 16, 2020, 03:52 PM |
| MARTIN JOHN C | Director | Oct 14, 2020 | Option Exercise | $16.15 | 205,260 | 3,314,949 | 1,876,564 | Oct 16, 2020, 03:51 PM |
| MARTIN JOHN C | Director | Oct 14, 2020 | Buy | $19.00 | 75,800 | 1,440,200 | 1,952,364 | Oct 16, 2020, 03:51 PM |
| Loven Jakob | Director | Oct 14, 2020 | Option Exercise | $16.15 | 169,031 | 2,729,851 | 1,545,344 | Oct 16, 2020, 03:49 PM |
| Belldegrun Arie | Director | Oct 14, 2020 | Option Exercise | $16.15 | 253,251 | 4,090,004 | 2,315,314 | Oct 16, 2020, 03:44 PM |
| Kosacz Barbara | COO & General Counsel | Oct 14, 2020 | Buy | $19.00 | 5,250 | 99,750 | 614,600 | Oct 16, 2020, 03:40 PM |
| Dinsmore Christopher | Chief Scientific Officer | Oct 14, 2020 | Buy | $19.00 | 5,250 | 99,750 | 5,250 | Oct 16, 2020, 03:39 PM |
| Al-Wakeel Yasir B. | Chief Financial Officer | Oct 14, 2020 | Buy | $19.00 | 5,250 | 99,750 | 37,219 | Oct 16, 2020, 03:38 PM |
| Bischofberger Norbert W. & Inger A. Revocable Inter Vivos Trust | 10% Owner | Oct 14, 2020 | Option Exercise | $16.15 | 185,758 | 2,999,992 | 4,274,996 | Oct 16, 2020, 03:36 PM |
| Bischofberger Norbert W. & Inger A. Revocable Inter Vivos Trust | 10% Owner | Oct 14, 2020 | Buy | $19.00 | 95,500 | 1,814,500 | 4,370,496 | Oct 16, 2020, 03:36 PM |
| BISCHOFBERGER NORBERT W | President & CEO | Oct 14, 2020 | Option Exercise | $16.15 | 185,758 | 2,999,992 | 4,274,996 | Oct 16, 2020, 03:29 PM |
| BISCHOFBERGER NORBERT W | President & CEO | Oct 14, 2020 | Buy | $19.00 | 95,500 | 1,814,500 | 4,370,496 | Oct 16, 2020, 03:29 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| BISCHOFBERGER NORBERT W | President & CEO | 05/18/2022 | 768,046 |
| BISCHOFBERGER NORBERT W | President & CEO | 05/17/2022 | 348,529 |
| BISCHOFBERGER NORBERT W | President & CEO | 05/19/2022 | 1,134,510 |
| Dinsmore Christopher | Chief Scientific Officer | 12/13/2021 | 140,845 |
| DiMartino Jorge | Chief Medical Officer & VP | 12/13/2021 | 202,893 |
| BISCHOFBERGER NORBERT W | President & CEO | 12/06/2021 | 173,492 |
| De Backer Marianne | Director | 12/01/2021 | 13,305 |
| Dinsmore Christopher | Chief Scientific Officer | 10/04/2021 | 30,048 |
| Dinsmore Christopher | Chief Scientific Officer | 10/04/2021 | 191,195 |
| Dinsmore Christopher | Chief Scientific Officer | 09/07/2021 | 30,048 |
| Dinsmore Christopher | Chief Scientific Officer | 09/07/2021 | 201,302 |
| De Backer Marianne | Director | 08/20/2021 | 19,565 |
| Dinsmore Christopher | Chief Scientific Officer | 08/02/2021 | 30,048 |
| Dinsmore Christopher | Chief Scientific Officer | 08/02/2021 | 189,165 |
| Loven Jakob | Director | 04/20/2021 | 433,185 |
| Loven Jakob | Director | 04/19/2021 | 288,278 |
| Loven Jakob | Director | 04/16/2021 | 696,762 |
| Loven Jakob | Director | 04/15/2021 | 540,536 |
| Loven Jakob | Director | 04/14/2021 | 744,029 |
| Loven Jakob | Director | 04/13/2021 | 405,793 |
| Loven Jakob | Director | 04/08/2021 | 1,730,487 |
| Loven Jakob | Director | 04/12/2021 | 415,896 |
| Loven Jakob | Director | 04/09/2021 | 589,152 |
| Omega Fund V, L.P. | 10% Owner | 10/14/2020 | 5,915,729 |
| Omega Fund V, L.P. | 10% Owner | 10/14/2020 | 8,550,000 |
| Stampacchia Otello | Director | 10/14/2020 | 5,915,729 |
| Stampacchia Otello | Director | 10/14/2020 | 8,550,000 |
| TANEN DAVID M | Director | 10/14/2020 | 599,472 |
| Ridloff Elena | Director | 10/14/2020 | 49,970 |
| MARTIN JOHN C | Director | 10/14/2020 | 3,314,949 |
| MARTIN JOHN C | Director | 10/14/2020 | 1,440,200 |
| Loven Jakob | Director | 10/14/2020 | 2,729,851 |
| Belldegrun Arie | Director | 10/14/2020 | 4,090,004 |
| Kosacz Barbara | COO & General Counsel | 10/14/2020 | 99,750 |
| Dinsmore Christopher | Chief Scientific Officer | 10/14/2020 | 99,750 |
| Al-Wakeel Yasir B. | Chief Financial Officer | 10/14/2020 | 99,750 |
| Bischofberger Norbert W. & Inger A. Revocable Inter Vivos Trust | 10% Owner | 10/14/2020 | 2,999,992 |
| Bischofberger Norbert W. & Inger A. Revocable Inter Vivos Trust | 10% Owner | 10/14/2020 | 1,814,500 |
| BISCHOFBERGER NORBERT W | President & CEO | 10/14/2020 | 2,999,992 |
| BISCHOFBERGER NORBERT W | President & CEO | 10/14/2020 | 1,814,500 |
Load More Insider Transactions
CHANGE IN SHARES OUTSTANDING
STOCK BUYBACKS
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Period of Report: 06/30/2021
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
03/31/2021
0.33%
1Q